Incio et al.85 reported that in vivo IL-6 inhibition and FGF-2 adjustment eliminate obesity-induced resistance to anti-VEGF therapy by impacting tumor cell growth, restoring tumor vasculature, alleviating hypoxia, and diminishing immunosuppression. Here, VEGFA is linked to obesity due to melanocortin 4 receptor deficiency.